What Steris's Quarter ended Sep 30, 2026 10-Q says: 5 signals
Steris filed its latest 10-Q with the SEC on Nov 5, 2026. It discusses acquisition announced, acquisition completed and international growth.
Public (STE)Medical Equipment Manufacturing10,000+ employeessteris.comLinkedIn
Get Steris' live signals in Claude or ChatGPT, or by API
What changed at Steris this week? Use Autobound signals for steris.com.- Filed
- Nov 5, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 15
Source: Autobound Signal API · 95 signals tracked for Steris · updated
10-Q · latest 10
What Steris's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 5 signals
STERIS to acquire Xodus Medical for $2.1 billion in cash plus $150 million earnout
On October 11, 2026, STERIS signed a definitive purchase agreement to acquire Xodus Medical for approximately $2.1 billion in cash at closing plus potential earnout consideration of up to $150.0 million, expecting to close by December 31, 2026.
$2.1B
cash at closing to acquire Xodus Medical
During Q2 fiscal 2027, STERIS recorded $25.5 million in total pre-tax restructuring expenses, including plans to consolidate chemistry manufacturing into North Carolina and optimize healthcare portfolios.
$25.5M
total pre-tax restructuring charges recorded in the quarter
STERIS announced the Fiscal 2027 Manufacturing Restructuring Plan to consolidate manufacturing and distribution for formulated chemistries to North Carolina, closing facilities in St.
Completed three tuck-in acquisitions in Healthcare segment for $17.3 million aggregate consideration
During the first six months of fiscal 2027, STERIS completed three tuck-in acquisitions in the Healthcare segment for approximately $17.3 million total aggregate consideration.
$17.3M
total aggregate consideration for three tuck-in acquisitions
Foreign revenues increased 8.5% to $388.2 million in second quarter across multiple regions
Revenues from other foreign locations grew 8.5% to $388.2 million for the second quarter and 8.7% to $761.4 million for the six months ended September 30, 2026, driven by growth in EMEA, Latin America, Asia Pacific, and Canada.
$388.2M
revenues from other foreign locations for the three months ended September 30, 2026
8.5%
increase in revenues from other foreign locations
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 5 signals
STERIS Announces Restructuring Plan with Expected Charges of $55 Million to $70 Million
STERIS announced a restructuring plan on August 5, 2026, to consolidate manufacturing and distribution of formulated chemistries to a new Center of Excellence in North Carolina, expecting pre-tax charges of $55 million to $70 million through fiscal 2030.
$70M
total pre-tax restructuring charges expected
Consolidating formulated chemistries manufacturing to new North Carolina Center of Excellence
On August 5, 2026, STERIS announced a targeted restructuring plan to consolidate formulated chemistries manufacturing and distribution into a new Center of Excellence in North Carolina, closing sites in St.
$70M
total pre-tax restructuring charges of approximately $55 million to $70 million
STERIS completed three tuck-in acquisitions for $17.3 million expanding Healthcare segment offerings
During the first three months of fiscal 2027, STERIS completed three tuck-in acquisitions for approximately $17.3 million in aggregate consideration to expand its Healthcare product and service offerings.
$17.3M
total aggregate consideration for three tuck-in acquisitions
Healthcare Segment Backlog Increases to $444.0 Million from $403.5 Million
Healthcare segment backlog reached $444.0 million at June 30, 2026, up from $403.5 million at June 30, 2025.
$444M
Healthcare segment backlog at June 30, 2026
International revenues increased across foreign locations, led by 28.7% growth in Ireland
Revenues from Ireland increased 28.7% to $29.0 million and other foreign revenues grew 8.8% to $373.2 million for the quarter.
$29M
Ireland revenues for the three months ended June 30, 2026
28.7%
increase in Ireland revenues
Earlier 10-Q filings
- 10-Q · Quarter ended Dec 31, 2025Filed · 5 signalsSEC EDGAR
Showing 10 of 15 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Steris earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Agreement to acquire Xodus Medical expands surgical consumablesThe company entered an agreement to acquire Xodus Medical, expanding single-use operating room consumables including patient positioning, patient warming, and handling products. Xodus brings direct OR commercial access, mid-teens revenue growth expectations, and EBIT margins in the low to mid-50s funded via debt. | |
| Revenue grew 9% to $1.6B with 45.3% gross marginSecond quarter as-reported revenue rose 9% to $1.6 billion, with constant currency organic revenue expanding 8% supported by 230 basis points of pricing. Adjusted gross margin reached 45.3%, benefiting from roughly $20 million in tariff refunds, while adjusted EBIT margin expanded 150 basis points to 24.6%. | |
| Life Sciences revenue surged 18% led by capital equipmentLife Sciences constant currency organic revenue expanded 18% in Q2, propelled by a 53% surge in capital equipment shipments, 9% consumables growth, and a $10 million single-customer order. Segment EBIT margins set a record at 44.4%, up 310 basis points, aided by reshoring trends. | |
| Fiscal 2027 diluted EPS guidance raised to $11.35-$11.55Full-year fiscal 2027 adjusted diluted EPS guidance was increased to a range of $11.35 to $11.55 from the prior $11.10 to $11.30 range. Management also raised Life Sciences constant currency organic growth outlook to 9%-10% from 6%-7% previously. | |
| Applied Sterilization Technologies fiscal 2027 growth outlook loweredManagement lowered constant currency organic revenue growth expectations for Applied Sterilization Technologies (AST) to 6% to 7%, down from the prior 7% to 8% range. The revision aligns the full-year forecast with the second quarter exit run-rate following soft procedure volumes. | |
| Second quarter capital expenditures totaled $76.1M across facilitiesSTERIS recorded capital expenditures of $76.1 million for the second quarter alongside $125.6 million in depreciation and amortization. Operational spending prioritized ongoing capacity loadings and facility investments across processing and manufacturing networks. |
Signal API · MCP
Track Steris with the Signal API
One POST /v1/companies/enrich call with steris.com returns Steris 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"steris.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Steris 10-Q
When did Steris file its latest 10-Q?
What did Steris disclose in its latest 10-Q?
What did Steris say on its recent earnings calls?
Where can I read Steris's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .